AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
161 hedge funds and large institutions have $712M invested in Aimmune Therapeutics in 2020 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 43 increasing their positions, 45 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
55% less capital invested
Capital invested by funds: $1.57B → $712M (-$858M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
161
Holding in Top 10
–
Calls
$6.47M
Puts
$5.23M
Top Buyers
| 1 | +$23.6M | |
| 2 | +$22.3M | |
| 3 | +$14.5M | |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$11.1M |
| 5 |
AC
Armistice Capital
New York
|
+$8.65M |
Top Sellers
| 1 | -$32.6M | |
| 2 | -$28.8M | |
| 3 | -$22.8M | |
| 4 |
Bank of New York Mellon
New York
|
-$6.23M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.2M |